Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1

Kobe Journal of Medical Sciences

Volumn 54, Issue 1, 2008, Pages 23-34

  Harada, Naozumi ^a,c,d   Hoshiai, Kiyotaka ^b   Takahashi, Yoshiyasu ^b   Sakaguchi, Yasue ^b   Kuno, Takayoshi ^c   Hishida, Tadashi ^a   Shiku, Hiroshi ^d  

^a ImmunoFrontier Inc   (Japan)

^b Fuji Biomedix Co Ltd   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccine; CHP NY ESO 1; Safety pharmacology

Indexed keywords

CANCER VACCINE; CHOLESTEROL BEARING HYDROPHOBIZED NY ESO 1 PEPTIDE VACCINE; POTASSIUM CHANNEL HERG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BODY PLETHYSMOGRAPH; BREATHING RATE; CANCER IMMUNIZATION; CANCER PATIENT; CARDIOVASCULAR SYSTEM; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; ENZYME INHIBITION; HEART RATE; HOLTER MONITORING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOTOR PERFORMANCE; NONHUMAN; PHARMACOLOGY; PILOT STUDY; RAT; RESPIRATORY SYSTEM; TELEMETRY; TIDAL VOLUME;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARDIOVASCULAR SYSTEM; CELL LINE; CENTRAL NERVOUS SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGICAL PHENOMENA; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MALE; MEMBRANE PROTEINS; MICROSCOPY, ELECTRON, TRANSMISSION; PATCH-CLAMP TECHNIQUES; RATS; RECOMBINANT PROTEINS;

EID: 45849113567     PISSN: 00232513     EISSN: 18830498     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M., and Nitti, D. 2004. Part I: Vaccines for solid tumours. Lancet Oncol. 11:681-9.
2. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117:1466-76.
3. Chen, Y. T., Scanlan, M. J., Sahin, U., Türeci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U. S. A. 94:1914-8.
4. Gnjatic, S., Nishikawa, H., Jungbluth, A. A., Güre, A. O., Ritter, G., Jäger, E., Knuth, A., Chen, Y. T., and Old, L. J. 2006. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95:1-30.
5. Akiyoshi, K., Kobayashi, S., Shichibe, S., Mix, D., Baudys, M., Kim, S. W., and Sunamoto, J. 1998. Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. J. Control Release 54:313-20.
6. Akiyoshi, K., Sasaki, Y., and Sunamoto, J. 1999. Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B. Bioconjug. Chem. 10:321-4.
7. van der Bruggen, P. and Van den Eynde, B. J. 2006. Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18:98-104.
8. Robins, R. A. 1986. T-cell responses at the host: tumour interface. Biochim. Biophys. Acta 865:289-305.
9. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281-355.
10. Hasegawa, K., Noguchi, Y., Koizumi, F., Uenaka, A., Tanaka, M., Shimono, M., Nakamura, H., Shiku, H., Gnjatic, S., Murphy, R., Hiramatsu, Y., Old, L. J., and Nakayama, E. 2006. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin. Cancer Res. 12:1921-7.
11. Uenaka, A., Wada, H., Isobe, M., Saika, T., Tsuji, K., Sato, E., Sato, S., Noguchi, Y., Kawabata, R., Yasuda, T., Doki, Y., Kumon, H., Iwatsuki, K., Shiku, H., Monden, M., Jungbluth, A. A., Ritter, G., Murphy, R., Hoffman, E., Old, L. J., and Nakayama, E. 2007. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 7:9-19.
12. Ikuta, Y., Katayama, N., Wang, L., Okugawa, T., Takahashi, Y., Schmitt, M., Gu, X., Watanabe, M., Akiyoshi, K., Nakamura, H., Kuribayashi, K., Sunamoto, J., and Shiku, H. 2002. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99:3717-24.
13. Kitano, S., Kageyama, S., Nagata, Y., Miyahara, Y., Hiasa, A., Naota, H., Okumura, S., Imai, H., Shiraishi, T., Masuya, M., Nishikawa, M., Sunamoto, J., Akiyoshi, K., Kanematsu, T., Scott, A. M., Murphy, R., Hoffman, E. W., Old, L. J., and Shiku, H. 2006. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin. Cancer Res. 12:7397-405.
14. Truett, A. A. and West, D. B. 1995. Validation of a radiotelemetry system for continuous blood pressure and heart rate monitoring in dogs. Lab. Anim. Sci. 45:299-302.
15. Krumpl, G., Todt, H., Schunder-Tatzber, S., and Raberger, G. 1989. Holter monitoring in conscious dogs. Assessment of arrhythmias occurring during ischemia and in the early reperfusion phase. J. Pharmacol. Methods 22:77-91.
16. Fridericia, L. S. 1920. Dir Systolendaeur in Elektrokardiogram bei normalen Menchen und bei Herzkranken. Acta Med. Scand. 53:469-86.
17. Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., and January, C. T. 1998. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. 74:230-41.
18. Hamill, O. P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F. J. 1981. Improve patch clamp techniques for high-resolution current recording from cells and cell-free membrane-patches. Pflügers Arch. 391:85-100.
19. Mattsson, J. L, Spencer, P. J., and Albee, R. R. 1996. A performance standard for clinical and functional observational battery examinations of rats. J. Am. Coll. Toxicol. 15:239-254.
20. McDaniel, K. L. and Moser, V. C. 1993. Utility of a neurobehavioral screening battery for differentiating the effects of two pyrethroids, permethrin and cypermethrin. Neurotoxicol. Teratol. 15:71-83.
21. Bartlett, D. and Tenney, S. M. 1970. Control of breathing in experimental anemia. Respir. Physiol. 10:384-395.
22. Harrington, K. J., Rowlinson-Busza, G., Syrigos, K. N., Uster, P. S., Vile, R. G., and Stewart, J. S. 2000. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin. Cancer Res. 6:2528-37.
23. Porter, C. J. and Charman, S. A. 2000. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci. 89:297-310.
24. Moriya, H., Maitani, Y., Shimoda, N., Takayama, K., and Nagai, T. 1997. Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharm. Res. 14:1621-8.
25. Corvo, M. L., Boerman, O. C., Oyen, W. J., Jorge, J. C., Cruz, M. E., Crommelin, D. J., and Storm, G. 2000. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharm. Res. 17:600-6.
26. Oussoren, C. and Storm, G. 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 50:143-56.